BioInvent was listed on the O-list at the Stockholm Stock Exchange in June 2001.
Business:
BioInvent was formed in 1996 and has established a leading position in the field of monoclonal antibodies and offers the international pharmaceutical industry a complete set of services from the design and selection of human monoclonal antibodies through to early stage process development and scale up. The cornerstone in the technology base is a library of several billion human antibody genes, n-CoDeRTM, and an officially certified, organisation and facility for manufacturing of complex antibody molecules.
BioInvent’s unique competence is based on skilled production engineers and research scientists. BioInvent intends to leverage its technology base further by investigating opportunities in the protein array field and by building a portfolio of proprietary antibody drugs. The company is located close to the University of Lund which enables fruitful collaborative research and exchange of ideas..